Miltefosine analogues with comparable antileishmanial activity and significantly reduced macrophage cytotoxicity
Carregando...
Data
Título da Revista
ISSN da Revista
Título de Volume
Editor
Resumo
BACKGROUND Miltefosine (MIL) is the only oral drug approved for leishmaniasis treatment, but its use is limited by
gastrointestinal toxicity. Novel alkylphospholipid analogues may provide safer and more effective alternatives.
OBJECTIVES This study aimed to assess the antileishmanial activity, cytotoxicity, and membrane interactions of three MIL
analogues TC387, TC388, and TC437 against Leishmania amazonensis.
METHODS Antileishmanial and cytotoxic activities were evaluated in L. amazonensis, J774.A1 macrophages, and erythrocytes.
Membrane interactions were characterized using spin-label electron paramagnetic resonance (EPR) spectroscopy.
FINDINGS TC387, TC388, and TC437 demonstrated EC50 values of 10-16 µM for intracellular amastigotes, compared to 17
µM for MIL, with selectivity indices (SI) ranging from 43-163, significantly higher than MIL’s SI of 5. EPR data revealed that
the analogues increased membrane protein dynamics and caused greater disruption at the lipid-protein interface of parasite
membranes relative to MIL. This disruption likely enhances pore formation, ion leakage, and reactive oxygen species (ROS)
production, leading to parasite death.
MAIN CONCLUSIONS The MIL analogues TC387, TC388, and TC437 exhibited superior SI and comparable or slightly enhanced
antileishmanial activity relative to MIL, along with very low hemolytic potential. These findings support further investigation of
these analogues as promising oral therapeutic candidates for leishmaniasis.
Descrição
Palavras-chave
Citação
ALONSO, Lais et al. Miltefosine analogues with comparable antileishmanial activity and significantly reduced macrophage cytotoxicity. Memórias do Instituto Oswaldo Cruz, Rio de Janeiro, v. 120, e240219, 2025. DOI: 10.1590/0074-02760240219. Disponível em: https://www.scielo.br/j/mioc/a/NzrDz6dqJmzY8G6vPR75wGD/?lang=en. Acesso em: 21 ago. 2025.